Clinical Trials Browser

NIH × Hereditary Breast and Ovarian Cancer Syndrome × Clear all

NCT02203513 2022-09-10

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Phase 2 Terminated

111 enrolled 15 charts

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Phase 1 Completed

98 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT00535119 2015-05-22

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1 Completed

107 enrolled

BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

NCT00321633 2013-08-26

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Phase 2 Completed

148 enrolled

BreastGynecologic

Breast Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome